Get the Stockscreener App
12.01
3.30%
-0.41
Neuropace Inc stock is traded at $12.01, with a volume of 65,268.
It is down -3.30% in the last 24 hours and up +9.68% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
See More
Previous Close:
$12.42
Open:
$12.41
24h Volume:
65,268
Relative Volume:
0.84
Market Cap:
$358.48M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-9.4567
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
+3.71%
1M Performance:
+9.68%
6M Performance:
+80.60%
1Y Performance:
-8.81%
1-Day Range:
$11.75
$12.50
1-Week Range:
$11.27
$12.53
52-Week Range:
$5.45
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.01 | 358.48M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace Inc (NPCE): A New Perspective - Stocks Register
NeuroPace Shares Updates on Financial Performance and Board of Directors - Defense World
NeuroPace Sees Rise in 4Q, Full-Year Sales - MarketWatch
NeuroPace Strengthens Board and Reports Strong 2024 Results - TipRanks
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates - The Manila Times
NeuroPace narrows FY24 revenue view to $79.4M-$79.9M from $78M-$80M - TipRanks
Neuropace, Inc. Appoints Scott Huennekens to Its Board of Directors - Marketscreener.com
NeuroPace Inc (NPCE) Trading Down 5.31% on Jan 8 - GuruFocus.com
Institutions profited after NeuroPace, Inc.'s (NASDAQ:NPCE) market cap rose US$37m last week but private equity firms profited the most - Simply Wall St
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $2.21 Million Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
When the Price of (NPCE) Talks, People Listen - Stock Traders Daily
Head to Head Analysis: Minerva Surgical (NASDAQ:UTRS) & NeuroPace (NASDAQ:NPCE) - Defense World
State Street Corp Increases Stock Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) versus NEXGEL (NASDAQ:NXGL) Head to Head Contrast - Defense World
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $14.50 - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.50 Average PT from Analysts - MarketBeat
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Nasdaq
NeuroPace to Present at J.P. Morgan's Prestigious Healthcare Conference in January 2025 - StockTitan
NeuroPace (NASDAQ:NPCE) Trading Up 4% – Should You Buy? - Defense World
NeuroPace (NASDAQ:NPCE) Price Target Raised to $14.00 - MarketBeat
JPMorgan sees NeuroPace stock undervalued, highlights clinically superior RNS device - Investing.com
NeuroPace (NASDAQ:NPCE) Trading Up 4%Should You Buy? - MarketBeat
NeuroPace's SWOT analysis: epilepsy treatment innovator's stock poised for growth - Investing.com
Perspective Therapeutics (NYSE:CATX) vs. NeuroPace (NASDAQ:NPCE) Head to Head Contrast - Defense World
Neurostimulation Market is experiencing new opportunities & - openPR
NPCENeuropace, Inc. Latest Stock News & Market Updates - StockTitan
NeuroPace to Host Investor Day on January 28th in New York City - The Manila Times
NeuroPace, Inc. Announces Investor Day to Discuss RNS Technology and Future Plans on January 28, 2025 - Nasdaq
NeuroPace Sets Investor Day to Showcase RNS Technology and Growth Strategy in Epilepsy Treatment - StockTitan
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet - MSN
How To Trade (NPCE) - Stock Traders Daily
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting - The Manila Times
NeuroPace's RNS System Shows 82% Seizure Reduction, Featured in 70+ Studies at AES 2024 - StockTitan
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar - Simply Wall St
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome - The Manila Times
NeuroPace Completes Groundbreaking Trial Enrollment for Severe Epilepsy Treatment Innovation - StockTitan
NeuroPace Inc (NPCE) Stock Price Up 7.36% on Dec 2 - GuruFocus.com
NeuroPace Inc (NPCE) Shares Up 3.41% on Nov 29 - GuruFocus.com
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $14.60 - Defense World
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com India
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat
NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News
NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
What Makes NeuroPace (NPCE) a New Buy Stock - MSN
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):